Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial

Pfizer (PFE) reported ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in Phase 2b trial.

Pfizer's report on its ultra-long-acting injectable GLP-1 RA indicates promising results in its Phase 2b trial, showcasing sustained weight loss with monthly dosing. This outcome could enhance Pfizer's portfolio, potentially impacting its market position within the growing diabetes and obesity treatments sector, leading to increased investor interest and possibly a positive shift in its stock trajectory.